| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053726121 |
| P356 | DOI | 10.1007/S00109-015-1352-5 |
| P698 | PubMed publication ID | 26658520 |
| P50 | author | Bart Vanhaesebroeck | Q64481959 |
| Roberto Piñeiro | Q78757221 | ||
| P2093 | author name string | Maria A Whitehead | |
| P2860 | cites work | p110δ, a novel phosphoinositide 3-kinase in leukocytes | Q24314825 |
| Twice upon a time: PI3K's secret double life exposed | Q24317406 | ||
| p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes | Q24319291 | ||
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling | Q24599676 | ||
| Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage | Q24603171 | ||
| Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome | Q24608709 | ||
| De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes | Q24627067 | ||
| Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA | Q24632718 | ||
| PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL) | Q26782633 | ||
| Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies | Q26866482 | ||
| PI3K signalling in inflammation | Q27690632 | ||
| Regulation of angiogenesis by PI3K signaling networks | Q38090346 | ||
| Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. | Q38149636 | ||
| The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. | Q38341764 | ||
| Management of adverse events associated with idelalisib treatment: expert panel opinion | Q38366294 | ||
| Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation. | Q38873867 | ||
| Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. | Q38924965 | ||
| High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models | Q38956648 | ||
| Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. | Q38974959 | ||
| High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation | Q39385359 | ||
| Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo | Q39446643 | ||
| Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation | Q39766760 | ||
| Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor | Q40726891 | ||
| Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. | Q40813898 | ||
| PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. | Q42481020 | ||
| PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models | Q42708522 | ||
| Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages | Q42799246 | ||
| Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. | Q44387429 | ||
| Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys. | Q54281359 | ||
| Cinderella finds her shoe: the first Vps34 inhibitor uncovers a new PI3K-AGC protein kinase connection. | Q54309767 | ||
| Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum | Q54356163 | ||
| The promise of combining inhibition of PI3K and PARP as cancer therapy | Q54472019 | ||
| PI3Kβ plays a critical role in neutrophil activation by immune complexes | Q54596986 | ||
| Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance | Q87375370 | ||
| PI3Kδ inhibition hits a sensitive spot in B cell malignancies | Q87482513 | ||
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials | Q27852946 | ||
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors | Q27853037 | ||
| Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
| PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? | Q28201583 | ||
| Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 | ||
| Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer | Q28241808 | ||
| Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils | Q28249042 | ||
| Signaling by the phosphoinositide 3-kinase family in immune cells | Q28283677 | ||
| Essential role for the p110delta phosphoinositide 3-kinase in the allergic response | Q28288981 | ||
| Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells | Q28546072 | ||
| PI 3-kinase p110beta: a new target for antithrombotic therapy | Q28588127 | ||
| Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation | Q28594707 | ||
| De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly | Q30647055 | ||
| Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase | Q33298503 | ||
| PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context | Q33674643 | ||
| Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits | Q33832537 | ||
| Activity of any class IA PI3K isoform can sustain cell proliferation and survival. | Q33952917 | ||
| Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency | Q34380652 | ||
| Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. | Q35129307 | ||
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer | Q35610581 | ||
| Signalling by PI3K isoforms: insights from gene-targeted mice. | Q36092041 | ||
| Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). | Q36279889 | ||
| The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases | Q36286414 | ||
| Inactivation of the Class II PI3K-C2β Potentiates Insulin Signaling and Sensitivity | Q36363079 | ||
| PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances | Q36516932 | ||
| Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer | Q36557786 | ||
| Genetic heterogeneity of diffuse large B-cell lymphoma | Q36567845 | ||
| p110δ PI3 kinase pathway: emerging roles in cancer | Q36647928 | ||
| Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism | Q36771317 | ||
| Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers | Q37003826 | ||
| Phosphoinositide 3-kinase p110δ promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization. | Q37391638 | ||
| Phosphoinositide 3-kinase p110γ in immunity | Q37908000 | ||
| Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer | Q38042638 | ||
| Therapeutic applications of PI3K inhibitors in cardiovascular diseases | Q38089742 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5-11 | |
| P577 | publication date | 2015-12-10 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Molecules in medicine mini-review: isoforms of PI3K in biology and disease | |
| P478 | volume | 94 |
| Q90180970 | CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway |
| Q38885442 | Defective phosphoinositide metabolism in autism |
| Q27711042 | Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946) |
| Q48684041 | Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity |
| Q41064013 | Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate |
| Q48133221 | Fibroblasts derived from patients with opsismodysplasia display SHIP2-specific cell migration and adhesion defects |
| Q93078908 | Function, Regulation and Biological Roles of PI3Kγ Variants |
| Q92758418 | Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor |
| Q98906864 | Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth |
| Q92077684 | Inhibition of PI3Kinase-α is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts |
| Q38603120 | Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury |
| Q38882099 | Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. |
| Q92702834 | Microglia Mediated Neuroinflammation: Focus on PI3K Modulation |
| Q64082434 | Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction |
| Q53645314 | New Therapies for Asthma and Chronic Obstructive Pulmonary Disease |
| Q49805542 | Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners |
| Q47111476 | Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. |
| Q89459605 | PI3K inhibitors in thrombosis and cardiovascular disease |
| Q92173331 | PI3K isoforms in cell signalling and vesicle trafficking |
| Q90379431 | PI3Kinase-p110δ Overexpression Impairs Dendritic Morphogenesis and Increases Dendritic Spine Density |
| Q60300789 | PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease |
| Q37623828 | PI3Kδ and primary immunodeficiencies. |
| Q33785941 | PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis |
| Q36274292 | PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors |
| Q89991493 | PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression |
| Q55254953 | Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. |
| Q93347159 | Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome |
| Q36117648 | Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies |
| Q52643680 | Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency. |
| Q39036639 | Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate |
| Q33832775 | Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling |
| Q47845996 | Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides |
| Q91977334 | Role of the PI3K/AKT pathway and PTEN in otitis media |
| Q29248893 | Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy |
| Q42683501 | The role of PI3Kα isoform in cardioprotection |
| Q39268911 | Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). |
Search more.